These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Compliance with hepatitis B and hepatitis C virus infection screening among HIV-1 infected patients in a resource-limited setting. Sungkanuparph S; Wongprasit P; Manosuthi W; Atamasirikul K Southeast Asian J Trop Med Public Health; 2008 Sep; 39(5):863-6. PubMed ID: 19058581 [TBL] [Abstract][Full Text] [Related]
24. Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors. Corral I; Quereda C; Moreno A; Pérez-Elías MJ; Dronda F; Casado JL; Muriel A; Masjuán J; Alonso-de-Leciñana M; Moreno S Cerebrovasc Dis; 2009; 27(6):559-63. PubMed ID: 19390181 [TBL] [Abstract][Full Text] [Related]
25. Complex regional pain syndrome in a HIV seropositive patient starting antiretroviral therapy. du Plessis CD; Aden AA; Firnhaber C; Sanne I J Clin Rheumatol; 2009 Oct; 15(7):371-2. PubMed ID: 20009979 [No Abstract] [Full Text] [Related]
26. Chronic viral hepatitis may diminish the gains of HIV antiretroviral therapy in sub-Saharan Africa. Cooper CL; Mills E; Wabwire BO; Ford N; Olupot-Olupot P Int J Infect Dis; 2009 May; 13(3):302-6. PubMed ID: 19004656 [TBL] [Abstract][Full Text] [Related]
27. Persistent differences in the antiviral effects of highly active antiretroviral therapy in the blood and male genital tract. Pasquier CJ; Moinard N; Sauné K; Souyris C; Lavit M; Daudin M; Izopet J; Bujan L AIDS; 2008 Sep; 22(14):1894-6. PubMed ID: 18753873 [No Abstract] [Full Text] [Related]
28. The long-term consequences of antiretroviral therapy: a review. Boyd M; Reiss P J HIV Ther; 2006 Jun; 11(2):26-35. PubMed ID: 16981593 [No Abstract] [Full Text] [Related]
29. Occult hepatitis B in persons infected with HIV is associated with low CD4 counts and resolves during antiretroviral therapy. Cohen Stuart JW; Velema M; Schuurman R; Boucher CA; Hoepelman AI J Med Virol; 2009 Mar; 81(3):441-5. PubMed ID: 19152397 [TBL] [Abstract][Full Text] [Related]
30. Treatment of facial lipoatrophy in HIV-infected patients. Prescrire Int; 2008 Aug; 17(96):170. PubMed ID: 19492497 [TBL] [Abstract][Full Text] [Related]
31. Response to Cicconi et al. 'Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?'. Núñez M AIDS; 2007 Jul; 21(12):1660. PubMed ID: 17630570 [No Abstract] [Full Text] [Related]
33. [Can antiretroviral treatment eradicate Prurigo nodularis in HIV infected patients?]. Ouattara I; Eholié SP; Aoussi E; Bissagnéne E; Raffi F Med Mal Infect; 2009 Jun; 39(6):415-6. PubMed ID: 19423251 [No Abstract] [Full Text] [Related]
34. A low antiretroviral activity of the antihepatitis B drug entecavir may be enough to select for M184V in HIV-1. Soriano V; Vispo E; Labarga P; Barreiro P AIDS; 2008 Apr; 22(7):911-2. PubMed ID: 18427216 [No Abstract] [Full Text] [Related]
35. Reconsidering the impact of conflict on HIV infection among women in the era of antiretroviral treatment scale-up in sub-Saharan Africa: a gender lens. Shannon K; Kaida A; Rachlis B; Lloyd-Smith E; Gray G; Strathdee SA AIDS; 2008 Sep; 22(14):1705-7. PubMed ID: 18753938 [No Abstract] [Full Text] [Related]
37. Gingival ulcers as first manifestation of leishmaniasis and HIV infection. Montineri A; La Rosa R; Larocca L; Brisolese V; Brancati G; Fatuzzo F; Nigro L AIDS; 2008 Jan; 22(1):160-1. PubMed ID: 18090409 [No Abstract] [Full Text] [Related]